| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
|
J Urol
|
2013
|
2.48
|
|
2
|
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
|
Blood
|
2011
|
2.37
|
|
3
|
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
|
J Clin Oncol
|
2010
|
2.25
|
|
4
|
Is single-incision laparoscopic cholecystectomy safe? Results of a systematic review and meta-analysis.
|
Surg Endosc
|
2013
|
2.02
|
|
5
|
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
|
Blood
|
2013
|
1.57
|
|
6
|
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
|
Blood
|
2008
|
1.52
|
|
7
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
|
J Clin Oncol
|
2014
|
1.44
|
|
8
|
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
|
J Clin Oncol
|
2010
|
1.42
|
|
9
|
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
|
Blood
|
2012
|
1.42
|
|
10
|
Age as a long-term prognostic factor in bariatric surgery.
|
Ann Surg
|
2012
|
1.25
|
|
11
|
Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis.
|
Surg Endosc
|
2012
|
1.11
|
|
12
|
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
|
J Clin Oncol
|
2008
|
1.10
|
|
13
|
Laparoscopy for rectal cancer is oncologically adequate: a systematic review and meta-analysis of the literature.
|
Surg Endosc
|
2014
|
1.02
|
|
14
|
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
|
Am J Hematol
|
2013
|
1.01
|
|
15
|
DCLK1 immunoreactivity in colorectal neoplasia.
|
Clin Exp Gastroenterol
|
2012
|
0.99
|
|
16
|
Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large noninvasive rectal lesions.
|
Surg Endosc
|
2013
|
0.99
|
|
17
|
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
|
Biol Blood Marrow Transplant
|
2012
|
0.98
|
|
18
|
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
|
Haematologica
|
2014
|
0.87
|
|
19
|
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
|
Ann Hematol
|
2014
|
0.85
|
|
20
|
High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
|
Acta Oncol
|
2005
|
0.84
|
|
21
|
High incidence of trocar site hernia after laparoscopic or robotic Roux-en-Y gastric bypass.
|
Surg Endosc
|
2014
|
0.84
|
|
22
|
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
|
Ann Hematol
|
2013
|
0.83
|
|
23
|
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.
|
Ann Hematol
|
2010
|
0.82
|
|
24
|
Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
|
Anal Quant Cytol Histol
|
2012
|
0.82
|
|
25
|
Pro-inflammatory cytokine production in chagasic mothers and their uninfected newborns.
|
J Parasitol
|
2009
|
0.81
|
|
26
|
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
|
Cancer
|
2011
|
0.81
|
|
27
|
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
|
Mech Ageing Dev
|
2012
|
0.81
|
|
28
|
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
|
Am J Hematol
|
2014
|
0.81
|
|
29
|
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
|
Farmaco
|
2003
|
0.79
|
|
30
|
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.
|
Haematologica
|
2011
|
0.79
|
|
31
|
Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
|
Anticancer Res
|
2013
|
0.79
|
|
32
|
Intraoperative vancomycin pharmacokinetics in cardiac surgery with or without cardiopulmonary bypass.
|
Ann Pharmacother
|
2013
|
0.78
|
|
33
|
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
|
J Clin Oncol
|
2013
|
0.76
|
|
34
|
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
|
Pancreas
|
2006
|
0.76
|
|
35
|
Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences.
|
Anticancer Res
|
2006
|
0.76
|
|
36
|
Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
|
Anticancer Res
|
2003
|
0.76
|
|
37
|
Should laparoscopic colorectal surgery still be considered unsafe?
|
Ann Surg
|
2012
|
0.75
|
|
38
|
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.
|
BMC Res Notes
|
2012
|
0.75
|
|
39
|
Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
|
Br J Haematol
|
2012
|
0.75
|
|
40
|
Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
|
Anticancer Res
|
2004
|
0.75
|
|
41
|
Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences.
|
Pharm World Sci
|
2004
|
0.75
|
|
42
|
Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
|
Am J Clin Oncol
|
2006
|
0.75
|
|
43
|
Pharmacokinetics of cyclosporine in recipients of marginal versus standard liver transplants.
|
Pharmacol Res
|
2006
|
0.75
|
|
44
|
A short course of granulocyte-colony-stimulating factor to accelerate wound repair in patients undergoing surgery for sacrococcygeal pilonidal cyst: proof of concept.
|
Cytotherapy
|
2012
|
0.75
|
|
45
|
Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
|
BJU Int
|
2012
|
0.75
|